These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22927101)

  • 1. Biomarkers for trials of neuroprotection in Parkinson's disease.
    Agarwal PA; Stoessl AJ
    Mov Disord; 2013 Jan; 28(1):71-85. PubMed ID: 22927101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging end points for monitoring neuroprotection in Parkinson's disease.
    Brooks DJ
    Ann Neurol; 2003; 53 Suppl 3():S110-8; discussion S118-9. PubMed ID: 12666103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of biomarkers and imaging in Parkinson's disease.
    Algarni MA; Stoessl AJ
    Expert Rev Neurother; 2016; 16(2):187-203. PubMed ID: 26829357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
    Löhle M; Reichmann H
    J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
    Marek K; Jennings D; Tamagnan G; Seibyl J
    Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.
    de la Fuente-Fernández R; Schulzer M; Mak E; Sossi V
    Parkinsonism Relat Disord; 2010 Jul; 16(6):365-9. PubMed ID: 20471298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
    Linazasoro G; Sesar A; Valldeoriola F; Compta Y; Herrero MT; Martínez Castrillo JC; López Lozano JJ; Bergaretxe A; Vela L; Fernández JM; Castro A; Kulisevski J; Lezcano E; Vaamonde J; López Del Val J; Chacón J; Vivancos F; Luquin R; Aguilar M; Burguera JA; Salvador C; Menéndez Guisasola L; Catalán MJ; Mir P; Campos V; Grandas F; Mínguez A; Balaguer E; Yáñez R; Leiva C; García Ruiz P; Cubo E
    Neurologia; 2009 Mar; 24(2):113-24. PubMed ID: 19322690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The search for biomarkers in Parkinson's disease: a critical review.
    Antoniades CA; Barker RA
    Expert Rev Neurother; 2008 Dec; 8(12):1841-52. PubMed ID: 19086880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical biomarkers of Parkinson disease.
    Wu Y; Le W; Jankovic J
    Arch Neurol; 2011 Jan; 68(1):22-30. PubMed ID: 21220674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic markers for Parkinson's disease.
    Chahine LM; Stern MB
    Curr Opin Neurol; 2011 Aug; 24(4):309-17. PubMed ID: 21464716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evidence for disease modification in Parkinson's disease.
    Lew MF
    Int J Neurosci; 2011; 121 Suppl 2():18-26. PubMed ID: 22035026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Parkinson's disease biomarkers.
    Prakash KM; Tan EK
    Expert Rev Neurother; 2010 Dec; 10(12):1811-25. PubMed ID: 21091313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.
    Streffer JR; Grachev ID; Fitzer-Attas C; Gomez-Mancilla B; Boroojerdi B; Bronzova J; Ostrowitzki S; Victor SJ; Fontoura P; Alexander R
    Mov Disord; 2012 Apr; 27(5):651-5. PubMed ID: 22508283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The conundrum of neuroprotection in Parkinson's disease.
    Antonini A
    Lancet Neurol; 2011 May; 10(5):396-7. PubMed ID: 21482192
    [No Abstract]   [Full Text] [Related]  

  • 20. Where do we stand on neuroprotection? Where do we go from here?
    Shoulson I
    Mov Disord; 1998; 13 Suppl 1():46-8. PubMed ID: 9613718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.